BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22613496)

  • 1. Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder.
    Zou Q; Xiong L; Yang Z; Lv F; Yang L; Miao X
    World J Surg Oncol; 2012 May; 10():92. PubMed ID: 22613496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of MK-1 and RegIV and its clinicopathological significances in the benign and malignant lesions of gallbladder.
    Yang L; Lan S; Liu J; Yang Z
    Diagn Pathol; 2011 Oct; 6():100. PubMed ID: 22018336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance.
    Cai W; Li Q; Yang Z; Miao X; Wen Y; Huang S; Ouyang J
    Clin Transl Oncol; 2013 Oct; 15(10):818-24. PubMed ID: 23475628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of DNA fragmentation factor 45 and thyroid transcription factor 1 expression in benign and malignant lesions of the gallbladder.
    Yuan Y; Yang ZL; Zou Q; Cao LF; Tan XG; Jiang S; Miao XY
    Pol J Pathol; 2013 Apr; 64(1):44-51. PubMed ID: 23625600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
    Xiong L; Deng X; Wen Y; Yang Z; Miao X
    World J Surg Oncol; 2013 Mar; 11():80. PubMed ID: 23531103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances.
    Shu GS; Lv F; Yang ZL; Miao XY
    Int J Clin Oncol; 2013 Aug; 18(4):641-50. PubMed ID: 22714709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressive levels of MUC1 and MUC5AC and their clinicopathologic significances in the benign and malignant lesions of gallbladder.
    Xiong L; Yang Z; Yang L; Liu J; Miao X
    J Surg Oncol; 2012 Jan; 105(1):97-103. PubMed ID: 21815153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of ephrin-A7 and metadherin and its clinicopathological significances in the benign and malignant lesions of gallbladder].
    Liu DC; Yang ZL
    Zhonghua Wai Ke Za Zhi; 2011 Mar; 49(3):250-5. PubMed ID: 21609571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
    Li Q; Yang Z
    J Exp Clin Cancer Res; 2009 May; 28(1):65. PubMed ID: 19445727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic significance of minichromosome maintenance protein 2 and Tat-interacting protein 30 expression in benign and malignant lesions of the gallbladder.
    Liu DC; Yang ZL
    Hum Pathol; 2011 Nov; 42(11):1676-83. PubMed ID: 21543106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma.
    Wang W; Yang ZL; Liu JQ; Yang LP; Yang XJ; Fu X
    Tumori; 2014; 100(6):667-74. PubMed ID: 25688501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of VHL and HIF-1α and Their Clinicopathologic Significance in Benign and Malignant Lesions of the Gallbladder.
    Yang Z; Yang Z; Xiong L; Huang S; Liu J; Yang L; Miao X
    Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):534-9. PubMed ID: 21415706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma.
    Liu DC; Yang ZL; Jiang S
    Pathol Oncol Res; 2011 Dec; 17(4):859-66. PubMed ID: 21455631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of annexin A1 (ANXA1) and A2 (ANXA2) and its significance in benign and malignant lesions of gallbladder].
    Yang LP; Yang ZL; Tan XG; Miao XY
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):595-9. PubMed ID: 21122411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of S1P1 and ERp29 expression to progression, metastasis, and poor prognosis of gallbladder adenocarcinoma.
    Yuan LW; Liu DC; Yang ZL
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):189-95. PubMed ID: 23558074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma.
    Liu DC; Yang ZL; Jiang S
    Cancer Biomark; 2010-2011; 8(3):113-21. PubMed ID: 22012766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CDX2 and hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic type and clinical outcome.
    Li QL; Yang ZL; Liu JQ; Miao XY
    Pathol Oncol Res; 2011 Sep; 17(3):561-8. PubMed ID: 21221877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRMS1 and HPA as Progression, Clinical Biological Behaviors, and Poor Prognosis-related Biomarkers for Gallbladder Adenocarcinoma.
    Yang Z; Liu F; Yang ZL
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):275-82. PubMed ID: 26200836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of enhancer of zesle homolog 2 and phosphatase and tension homolog and its clinicopathological significance in benign and malignant lesion of gallbladder].
    Liu DC; Yang ZL; Yang LP
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 33(7):618-22. PubMed ID: 18667776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expressions of HMGA2 and Thy1 in extrahepatic cholangiocarcinoma and their clinicopathological significances.
    Liu R; Yang Z; Huang S; Li D; Zou Q; Yuan Y
    Surg Oncol; 2019 Jun; 29():41-47. PubMed ID: 31196492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.